{'fraction_non_alphanumeric': 0.030636292223095052, 'fraction_numerical': 0.025923016496465043, 'mean_word_length': 5.009433962264151, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Single-dose preventive treatment of urinary tract infections after endoscopic resection of the prostate].

The ability of mezlocillin to prevent urinary tract infection after trans-urethral prostatectomy was evaluated in a randomized trial involving 100 patients (49 treated and 51 controls) with bacteria-free urine prior to surgery. One single 2 g dose of the antibiotic was administered intravenously 1 hour before the operation. Mezlocillin was chosen on the results of a preliminary study of post-trans-urethral prostatectomy urinary tract infections in 150 patients and was given as a single dose to prevent the development of multiresistant strains. Both groups of patients were comparable with regard to age, percentage of malignant tumours, weight of resected tissue and duration of post-operative bladder catheterization. Following surgery, bacteriuria (greater than or equal to 10(5) organisms/ml) was present in 18.4% of treated patients and in 51% of controls (p less than 0.001), the difference being significant on the 2nd and 5th post-operative days (p less than 0.01 and p less than 0.05 respectively). Clinical signs of infection were less frequent, and the duration of post-operative stay in hospital was reduced by more than 1 day in the treated group.